From: Systemic therapy in the management of metastatic or advanced salivary gland cancers
Treatment | ACC | MEC | ADC | ||||
---|---|---|---|---|---|---|---|
Author | Regimen | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses | Nb of patients | Nb of objective responses |
Licitra et al 7 | Cisplatin 100 mg/m² every 3w | 13 | 2 | 5 | 1 | 5 | 0 |
DeHann et al 9 | Cisplatin 50–120 mg/m² every 4w | 10 | 0 | - | - | - | - |
Suen et al 13 | Cisplatin | 14 | 9 | - | - | - | - |
Kaplan et al 14 | Cisplatin 100 mg/m² | 17 | 10 | - | - | - | - |
Jones et al 40 | Cisplatin 100 mg/m² | 2 | 0 | 2 | 1 | 3 | 0 |
Schramm et al 8 | Cisplatin 80-100 mg/m² every 4–6 w | 10 | 7 | - | - | - | - |
Mattox et al 10 | Mitoxantrone 12 mg/m² every 3w | 18 | 1 | - | - | - | - |
Verweij et al 11 | Mitoxantrone 14 mg/m² every 3w | 32 | 4 | - | - | - | - |
Vermoken et al 12 | Epirubicin 30 mg/m² weekly, if no response, 90 mg/m² every 3 w. | 20 | 2 | - | - | - | - |
Suen et al 13 , Kaplan et al 14 | Doxorubicin (various schema) | 7 | 3 | - | - | - | - |
Airoldi et al 15 | Vinorelbine 30 mg/m² weekly | 13 | 2 | - | - | 5 | 2 |
Spiers et al 16 Tannock et al 17 | Cyclophosphamide 100 mg/m² every 3 w | 7 | 0 | 0 | 0 | 0 | 0 |
Tannock et al 17 , Suen et al 13 , Kaplan et al 14 | 5-Fluorouracil (various schema) | 38 | 16 | - | - | - | - |
Tannock et al 17 , Suen et al 13 , Kaplan et al 14 | Methotrexate (various schema) | 10 | 0 | 5 | 2 | 1 | 0 |
Gilbert et al 18 | Paclitaxel 200 mg/m² every 3 w. | 14 | 0 | 14 | 3 | 17 | 5 |
Raguse et al 19 | Docetaxel 100 mg/m² every 3 w | - | - | 4 | 4 | - | - |
Van Herpen et al 21 | Gemcitabine 1250 mg/m² d1 and d8 every 3 w. | 21 | 0 | - | - | - | - |